Developing a New qPCR-Based System for Screening Mutation.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Accurate genotyping is crucial for effective lung cancer targeted therapy.
• Existing mutation detection methods may have limitations in clinical settings.

Purpose of the Study:

• To develop and evaluate a novel quantitative polymerase chain reaction (qPCR)-based mutation detection system, MASS-PCR.
• To assess the accuracy and convenience of MASS-PCR for detecting lung cancer driver gene mutations.

Main Methods:

• Developed a mutation-selected amplification-specific system PCR (MASS-PCR) using specific primers and probes.
• Analyzed 717 lung cancer specimens (fresh and FFPE) for mutations in EGFR, KRAS, BRAF, HER2, MET, ALK, and ROS1.
• Compared MASS-PCR results with amplification refractory mutation system PCR (ARMS-PCR) and next-generation sequencing (NGS), verified by direct sequencing.

Main Results:

• MASS-PCR demonstrated high consistency with ARMS-PCR (kappa > 0.733) and NGS (kappa = 0.79).
• Direct sequencing results supported MASS-PCR in cases of discrepancy with ARMS-PCR.
• The method proved sensitive and reliable across various sample types.

Conclusions:

• MASS-PCR is a convenient, accurate, and economical method for detecting lung cancer driver gene mutations.
• This system is suitable for clinical practice, aiding in personalized lung cancer treatment.
• MASS-PCR offers a reliable alternative for genotyping in oncology.